Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

558 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.
Zhang L, Yan X, Fox KAA, Willmann S, Nandy P, Berkowitz SD, Hermanowski-Vosatka A, Weitz JI, Solms A, Schmidt S, Patel M, Peters G. Zhang L, et al. Among authors: weitz ji. J Thromb Thrombolysis. 2020 Jul;50(1):20-29. doi: 10.1007/s11239-020-02077-9. J Thromb Thrombolysis. 2020. PMID: 32323192 Free PMC article. Clinical Trial.
Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial.
Mehta SR, Steg PG, Granger CB, Bassand JP, Faxon DP, Weitz JI, Afzal R, Rush B, Peters RJ, Natarajan MK, Velianou JL, Goodhart DM, Labinaz M, Tanguay JF, Fox KA, Yusuf S; ASPIRE Investigators. Mehta SR, et al. Among authors: weitz ji. Circulation. 2005 Mar 22;111(11):1390-7. doi: 10.1161/01.CIR.0000158485.70761.67. Circulation. 2005. PMID: 15781750 Clinical Trial.
Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers.
Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, Raghoebar M, Patel MR, Weitz JI, Levy JH. Levi M, et al. Among authors: weitz ji. J Thromb Haemost. 2014 Sep;12(9):1428-36. doi: 10.1111/jth.12599. Epub 2014 Jul 24. J Thromb Haemost. 2014. PMID: 24811969 Free article. Clinical Trial.
Guidance, guidelines, and communications.
Douketis JD, Weitz JI. Douketis JD, et al. Among authors: weitz ji. J Thromb Haemost. 2014 Oct;12(10):1744-5. doi: 10.1111/jth.12708. Epub 2014 Sep 30. J Thromb Haemost. 2014. PMID: 25156403 Free article. No abstract available.
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
Beyer-Westendorf J, Lensing AW, Arya R, Bounameaux H, Cohen AT, Wells PS, Middeldorp S, Verhamme P, Hughes R, Kucher N, Pap AF, Trajanovic M, Prins MH, Prandoni P, Weitz JI. Beyer-Westendorf J, et al. Among authors: weitz ji. Thromb Res. 2017 Jan;149:29-37. doi: 10.1016/j.thromres.2016.11.014. Epub 2016 Nov 21. Thromb Res. 2017. PMID: 27886530 Clinical Trial.
558 results